Global Orexin Receptor Antagonists Market, By Dosage (5mg, 10mg, 15mg, and 20mg), Drugs (Suvorexant, Lemborexant, Others), Application (Insomnia, Depression, Anxiety, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Orexin Receptor Antagonists Market Analysis and Size
The global orexin receptor antagonists market is expected to witness significant growth during the forecast period. Orexin Receptor Antagonists (ORAs) have been approved to treat insomnia, and suvorexant was the first agent supported at an optimal dose of 20 mg daily. Overall, ORAs have shown promising potential for treating insomnia in patients with OSA. Additionally, several clinical studies by NCBI in 2015 showed that placebo therapy for insomnia is also efficient for patients who are hampering the growth of the global ORA market.
Data Bridge Market Research analyses a growth rate in the global orexin receptor antagonists market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Orexin Receptor Antagonists Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Dosage (5mg, 10mg, 15mg, and 20mg), Drugs (Suvorexant, Lemborexant, Others), Application (insomnia, Depression, Anxiety, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Eisai Co., Ltd (Japan), Sun Pharmaceutical Industries Ltd. (India), Novartis AG (Switzerland), Endo Pharmaceuticals plc (Ireland), Mylan N.V. (U.S.), Mayne Pharma Group Limited (Australia), Teva Pharmaceutical Industries Ltd (Israel), Amneal Pharmaceutical Inc (U.S.), Mayne Pharma Group Limited (Australia), Merck KGaA (Germany), Sanofi (France), Currax Pharmaceuticals LLC (India)
|
|
Market Opportunities
|
|
Market Definition
Orexin receptor antagonists are the type of therapeutics used in the treatment of sleep disorders, characterized by difficulties or problems with sleep onset. It either bind or inhibits the action of orexin receptor. Orexin plays a vital role in the sleep–wake cycle through a complex interplay between the monoaminergic/cholinergic (wake-promoting) and gamma-aminobutyric acidergic (sleep-promoting) neuronal systems.
Global Orexin Receptor Antagonists Market Dynamics
Drivers
- Increased Clinical Research
There has been advanced clinical research that is boosting the growth of the market. For instance, daridorexant showed good safety and tolerance profile in OSA patients.In a 2020 randomized, placebo-controlled study, no clinically or statistically significant differences were found in AHI between daridorexant and placebo. Thus, it boosts the market growth.
- Technological Development
Increased technological developments in the pharmaceutical sector to manufacture advanced tricyclic antidepressant drugs is anticipated to boost remunerative opportunities for the expansion of the global orexin receptor antagonists market during the forecast period 2022-2029. Additionally, the presence of key manufacturing companies to develop antidepressant drugs boost growth of the market.
Opportunities
- Increasing Cases of Insomnia
Insomnia is the major contributor to the market in 2020, and is projected to remain dominant during the forecast period, mainly due to the rise in healthcare awareness, increase in the occurrence of sleep apnea, reduction in physical exercise by the population and growth in the geriatric population. As per the records of the American Academy of Sleep Medicine AASM) in 2014, insomnia affects 30% of adults, 15-20% have short-term insomnia and 10% of adults have chronic insomnia worldwide. All these factors contributes to create opportunity to the market.
Restraints/Challenges
- Availability of other Alternatives
The wide availability of several alternatives other than orexin receptor antagonists can hamper the market growth.Though suvorexant (Orexin Receptors Antagonist) is the best drug that is available against insomnia, other classes of drugs such as Benzodiazepines, Antidepressants, Non-benzodiazepines, Melatonin Antagonist and medical devices such as 2Breathe Sleep Inducer, Dreem Headband, Sleep Shepherd Blue, Fisher Wallace Stimulator, SR1 Delta Sleeper can also be used to treat insomnia which can negatively hamper the market growth.
- High Negligence towards Insomnia Treatment
The increased negligence towards the treatment of insomnia hamper the market growth. In National Sleep Foundation (NSF) stated that in 2010, only 15% of people were diagnosed with insomnia and only 6% received the same treatment. Common negligence among the people about insomnia and the associated side effects of drugs such as headache, sleepiness, next day drowsiness, weight loss restricts the patients from using this medication.
This global orexin receptor antagonists market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global orexin receptor antagonists market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Orexin Receptor Antagonists Market Scope
The global orexin receptor antagonists market is segmented on the basis of dosage, drugs, application, route of administration, end-users, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Dosage
- 5mg
- 10mg
- 15mg
- 20mg
Drugs
- Suvorexant
- Lemborexant
- Others
Application
- Insomnia
- Depression
- Anxiety
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Orexin Receptor Antagonists Market Regional Analysis/Insights
The global orexin receptor antagonists market is analyzed and market size insights and trends are provided by dosage, drug, application, route of administration, end-users, distribution channel as referenced above.
The major countries covered in the global orexin receptor antagonists market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the global orexin receptor antagonists market because of the global leaders in research and development activities, and increase in number of FDA approval drugs.
Asia-Pacific is considered to have lucrative growth because of the developing healthcare facilities, large number of generic manufacturers and increase in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Orexin Receptor Antagonists Market Share Analysis
The global orexin receptor antagonists market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global orexin receptor antagonists market
Key players operating in the global orexin receptor antagonists market include:
- Sun Pharmaceutical Industries Ltd. (India)
- Novartis AG (Switzerland)
- Endo Pharmaceuticals plc (Ireland)
- Zydus Cadila (India)
- Mylan N.V. (U.S.)
- Mayne Pharma Group Limited (Australia)
- Teva Pharmaceutical Industries Ltd (Israel)
- Amneal Pharmaceutical Inc (U.S.)
- Mayne Pharma Group Limited (Australia)
- Eisai Co., Ltd (Japan)
- Merck KGaA (Germany)
- Sanofi (France)
- Currax Pharmaceuticals LLC (India)
SKU-